-
1.发明申请Bile Acid Derivatives as FXR Ligands for the Prevention or Treatment of FXR-Mediated Diseases or Conditions 有权胆酸衍生物作为FXR配体用于预防或治疗FXR介导的疾病或病症公开(公告)号：US20150359805A1
公开(公告)日：2015-12-17
申请号：US14743295
申请日：2015-06-18
IPC分类号： A61K31/575
CPC分类号： A61K31/575 , C07J9/00 , C07J31/006
摘要： The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
摘要翻译： 本发明涉及式（I）的化合物：其中R是氢或α-羟基，位置7的羟基位于α或β位; 及其药学上可接受的盐，溶剂合物或氨基酸缀合物。
-
公开(公告)号：US10987362B2
公开(公告)日：2021-04-27
申请号：US16228944
申请日：2018-12-21
IPC分类号： A61K31/575 , A61P1/16 , A61K9/00
摘要： The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.
-
公开(公告)号：US09763964B2
公开(公告)日：2017-09-19
申请号：US14743295
申请日：2015-06-18
IPC分类号： A61K31/575 , C07J9/00 , C07J31/00
CPC分类号： A61K31/575 , C07J9/00 , C07J31/006
摘要： The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
-
4.发明申请Bile Acid Derivatives as FXR Ligands for the Prevention or Treatment of FXR-Mediated Diseases or Conditions 有权胆酸衍生物作为FXR配体用于预防或治疗FXR介导的疾病或病症公开(公告)号：US20140057886A1
公开(公告)日：2014-02-27
申请号：US14012401
申请日：2013-08-28
IPC分类号： C07J31/00
CPC分类号： A61K31/575 , C07J9/00 , C07J31/006
摘要： The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
摘要翻译： 本发明涉及式（I）的化合物：其中R是氢或α-羟基，位置7的羟基位于α或β位; 及其药学上可接受的盐，溶剂合物或氨基酸缀合物。
-
公开(公告)号：US20170165277A1
公开(公告)日：2017-06-15
申请号：US15299559
申请日：2016-10-21
IPC分类号： A61K31/575
CPC分类号： A61K31/575 , A61K31/56
摘要： The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.
-
6.发明授权Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions 有权胆酸衍生物作为FXR配体，用于预防或治疗FXR介导的疾病或病症公开(公告)号：US09090652B2
公开(公告)日：2015-07-28
申请号：US14012401
申请日：2013-08-28
IPC分类号： A61K31/575 , C07J9/00 , C07J31/00
CPC分类号： A61K31/575 , C07J9/00 , C07J31/006
摘要： The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
摘要翻译： 本发明涉及式（I）的化合物：其中R是氢或α-羟基，位置7的羟基位于α或β位; 及其药学上可接受的盐，溶剂合物或氨基酸缀合物。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.014 秒)
